COSCIENS Biopharma faced a substantial setback with the wind-down of its biopharmaceutical segment following clinical and insolvency challenges. The company is pivoting toward commercializing oat-derived natural active ingredients using proprietary Ethanol Fractionation Processes and PGX Technology. Despite a near 22% revenue decline in 2025, cost savings initiatives and technology-driven product innovation underpin its repositioning efforts. Liquidity remains sufficient to support operations through 2027, while R&D investment transitions away from pharmaceuticals toward scalable natural bioactives.